SL-901

SL-901 is an oral small molecule inhibitor targeting the phosphatidylinositol 3-kinase (PI3K) family and DNA-dependent protein kinase (DNA-PK). It has demonstrated activity against PI3K alpha, PI3K delta, and PIK3C2 beta isoforms. The drug was developed for the treatment of advanced solid tumors and has shown preclinical antitumor activity across various tumor types. Its mechanism involves inhibition of key signaling pathways involved in cancer cell growth and survival. The primary developer is Stemline Therapeutics, with UCB Pharma as the originator. Clinical development reached Phase 1 trials in patients with advanced solid tumors; however, these studies were terminated after consideration of similar drugs in development and evolving standards of care[2][3][4][5].